Purchased this stock at .85 cents on the 15th, based on an article on oct 10th, today news came out states:
Regulatory Approval: The approval from China's National Medical Products Administration (NMPA) for the Phase 2b PALIZADE trial signifies regulatory confidence in the potential of zetomipzomib. Regulatory approvals are critical milestones in drug development, enhancing the credibility and prospects of the drug's success.
Innovative Treatment: Zetomipzomib is described as a novel, first-in-class selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. The introduction of innovative treatments into the market, especially those targeting conditions with unmet medical needs like lupus nephritis, can lead to significant commercial success.
Strategic Collaboration and Market Rights: Everest Medicines' partnership with Kezar Life Sciences and the exclusive rights to develop and commercialize zetomipzomib in key Asian markets (Greater China, South Korea, and Southeast Asia) open substantial market opportunities. Access to these markets, particularly China with its large patient population for lupus nephritis, presents a significant growth avenue for Everest and by extension, for Kezar through collaboration.
Potential Market Impact: The emphasis on addressing lupus nephritis, a common and severe autoimmune disease leading to kidney failure, targets a considerable market need. Successful trial outcomes could position zetomipzomib as a leading treatment option, driving demand and generating substantial revenue.
Overall, the combination of regulatory approval, the introduction of a potentially groundbreaking treatment, strategic collaborations, and access to large markets underlines a bullish outlook for Everest Medicines and Kezar Life Sciences, reflecting investor optimism about their future growth and profitability.
Sold for a quick 13% profit, if we move back lower ill re buy, if not eh. If i get back in and we head into the 85 cents, target 1.37 which is 618 on the micro, or 2.25 which is 618 on the macro.
good luck traders.
Regulatory Approval: The approval from China's National Medical Products Administration (NMPA) for the Phase 2b PALIZADE trial signifies regulatory confidence in the potential of zetomipzomib. Regulatory approvals are critical milestones in drug development, enhancing the credibility and prospects of the drug's success.
Innovative Treatment: Zetomipzomib is described as a novel, first-in-class selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. The introduction of innovative treatments into the market, especially those targeting conditions with unmet medical needs like lupus nephritis, can lead to significant commercial success.
Strategic Collaboration and Market Rights: Everest Medicines' partnership with Kezar Life Sciences and the exclusive rights to develop and commercialize zetomipzomib in key Asian markets (Greater China, South Korea, and Southeast Asia) open substantial market opportunities. Access to these markets, particularly China with its large patient population for lupus nephritis, presents a significant growth avenue for Everest and by extension, for Kezar through collaboration.
Potential Market Impact: The emphasis on addressing lupus nephritis, a common and severe autoimmune disease leading to kidney failure, targets a considerable market need. Successful trial outcomes could position zetomipzomib as a leading treatment option, driving demand and generating substantial revenue.
Overall, the combination of regulatory approval, the introduction of a potentially groundbreaking treatment, strategic collaborations, and access to large markets underlines a bullish outlook for Everest Medicines and Kezar Life Sciences, reflecting investor optimism about their future growth and profitability.
Sold for a quick 13% profit, if we move back lower ill re buy, if not eh. If i get back in and we head into the 85 cents, target 1.37 which is 618 on the micro, or 2.25 which is 618 on the macro.
good luck traders.
交易开始:
Loading up again here. .84 cents